Seasonique Shortage: What Providers and Prescribers Need to Know in 2026

Extended-cycle oral contraceptives have become a standard of care for many reproductive-age patients — not just for contraception, but for managing endometriosis, dysmenorrhea, premenstrual dysphoric disorder (PMDD), and polycystic ovary syndrome (PCOS). Seasonique (levonorgestrel 0.15 mg / ethinyl estradiol 0.03 mg × 84 days plus ethinyl estradiol 0.01 mg × 7 days) is one of the most prescribed extended-cycle options. If your patients are struggling to fill it, this briefing covers what you need to know for 2026.

Current Availability Status (Early 2026)

As of early 2026, Seasonique is not on the FDA Drug Shortage Database. However, real-world availability remains inconsistent across regions and pharmacy chains. The availability situation is best described as "patchy" — some regions and pharmacy chains stock it reliably, while others see frequent out-of-stock events. Extended-cycle generics (particularly Ashlyna and Camrese in some areas) have experienced intermittent availability gaps.

The absence of a formal FDA shortage designation does not mean patients can reliably fill prescriptions. Providers should proactively discuss availability with patients and update prescribing practices to maximize pharmacist flexibility.

Root Causes of the Supply Challenge

Several overlapping factors drive the persistent availability challenges for extended-cycle levonorgestrel/ethinyl estradiol products:

• Manufacturing concentration: Generic oral contraceptives are produced at a small number of facilities globally. API sourcing for levonorgestrel and ethinyl estradiol is concentrated in Asian markets, creating vulnerability to supply chain disruptions.
• Low pharmacy turnover: 91-day packs are refilled only four times per year. Pharmacy inventory algorithms may not prioritize reordering, leading to stock gaps even when manufacturer supply is adequate.
• Increased clinical demand: Greater clinical adoption of extended-cycle regimens for non-contraceptive indications has increased overall demand beyond historical supply projections.

Prescribing Strategies to Maximize Patient Access

Write prescriptions generically. Prescribing as 'Levonorgestrel 0.15 mg / Ethinyl Estradiol 0.03 mg extended-cycle tablets, 91-day supply — generic acceptable' gives pharmacists maximum dispensing flexibility. They can dispense whichever of the six AB-rated equivalents (Amethia, Ashlyna, Camrese, Daysee, Jaimiess, Simpesse) is currently in stock.

Review existing prescriptions for brand-only designations. If you have patients whose previous prescriptions specify brand-name only, consider updating them to allow generic substitution. A brief telehealth note or MyChart message can accomplish this without a full visit.

Document the clinical indication. For patients using Seasonique for non-contraceptive indications (endometriosis, PMDD, dysmenorrhea), document the clinical reason. This supports insurance coverage and creates a paper trail if prior authorization is needed for a less common generic.

Therapeutic Substitutes When No Extended-Cycle Product Is Available

When no AB-rated generic of Seasonique is available, consider the following therapeutic alternatives by clinical scenario:

• Different 84/7 extended-cycle with placebo final week: Seasonale, Jolessa, Quasense, or Introvale contain the same active ingredient doses for 84 days but use inert tablets for the final 7 days (vs. low-dose estrogen in Seasonique). This may increase breakthrough bleeding during the final week. No washout needed when switching AB-rated products.
• Lower-dose extended cycle: Lo Seasonique (Amethia Lo, Camrese Lo, LoJaimiess) uses levonorgestrel 0.10 mg / EE 0.02 mg for 84 days plus EE 0.01 mg for 7 days. Consider for patients with estrogen-sensitive side effects, with counseling on potentially higher unscheduled bleeding rates.
• Continuous use of a monophasic 28-day COC: Prescribing levonorgestrel/EE 0.15/0.03 in continuous fashion (skip placebo week, start new active pack) is well-supported clinically. This is particularly useful when no extended-cycle product is available and the patient has an existing prescription for a 28-day pill.
• Long-acting reversible contraception (LARC): For patients primarily seeking period suppression, Mirena IUD (8 years), Liletta IUD (8 years), or Nexplanon implant (3 years) are highly effective and eliminate or significantly reduce menstrual bleeding in most patients. Consider counseling patients on these options proactively.

Switching Guidance

When switching between AB-rated Seasonique generics: no washout period required; patients can transition pack-to-pack. When switching to a non-equivalent extended-cycle formulation (e.g., Seasonale/Jolessa), advise 7 days of backup contraception if switching mid-cycle. Document the reason for the switch (medication availability) in the patient chart for insurance purposes.

Cost and Access Considerations

Under the ACA contraceptive mandate, most ACA-compliant plans cover at least one extended-cycle levonorgestrel/EE product at $0. Plans vary in which specific generics are covered. For uninsured or underinsured patients:

• GoodRx and SingleCare coupons can reduce generic prices to $20–$50 per 91-day pack
• Title X family planning clinics provide contraception at low or no cost based on income
• Planned Parenthood locations offer birth control services regardless of insurance status
• NeedyMeds.org and RxAssist.org maintain databases of patient assistance programs

Tools to Help Your Patients Find Seasonique

medfinder's provider dashboard at medfinder.com/providers allows you to check real-time availability of Seasonique and its generics at pharmacies near your patients before writing a prescription. You can also direct patients directly to medfinder to search on their own and receive results by text.

For a deeper dive into patient-facing strategies, see our companion post: How to help your patients find Seasonique in stock.